Novartis has gained regulatory approval in Switzerland for Coartem Baby, becoming the first to offer a malaria treatment tailored to newborns and young infants. The new formulation includes a dose strength and form designed specifically for this vulnerable population, addressing a critical gap in malaria therapeutics. Novartis will provide the drug largely on a not-for-profit basis to enhance accessibility in endemic regions.